Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

Also called NCT02449603

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02449603
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02449603. Randomized; no masking; primary purpose treatment. Start 2015-11 (actual); primary completion 2018-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Exenatide
Intervention (Drug)
Biphasic insulin Aspart 30
Lead sponsor
Xijing Hospital (class: other)
Collaborator
Air Force Military Medical University, China (class: other)
Collaborator
First Affiliated Hospital Xi'an Jiaotong University (class: other)
Collaborator
Second Affiliated Hospital of Xi'an Jiaotong University (class: other)
Collaborator
Shaanxi Provincial People's Hospital (class: other)
Collaborator
Chang'An Hospital (class: other)
Collaborator
Xi'an Gaoxin Hospital (class: other)
Collaborator
Xi'an Central Hospital (class: other)
Collaborator
Shaanxi Aerospace Hospital (class: not stated)

Record details

Record id
cardio:ct-nct02449603
Content hash
b233a22fc6a71b7f1c6ec360e31ab546cb7c71ab93a06fbcfd888296b9ca2a62